NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Last Close
Jul 02 04:00PM ET
1.20
Dollar change
+0.03
Percentage change
2.13
%
Index- P/E- EPS (ttm)-0.11 Insider Own2.46% Shs Outstand8.81M Perf Week-0.01%
Market Cap10.57M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float8.60M Perf Month3.45%
Enterprise Value9.57M PEG- EPS next Q- Inst Own2.82% Short Float0.45% Perf Quarter9.09%
Income-1.03M P/S23.49 EPS this Y- Inst Trans1.98% Short Ratio1.19 Perf Half Y-17.53%
Sales0.45M P/B1.95 EPS next Y- ROA-18.71% Short Interest0.04M Perf YTD-40.76%
Book/sh0.62 P/C9.27 EPS next 5Y- ROE-26.83% 52W High3.05 -60.66% Perf Year-51.61%
Cash/sh0.13 P/FCF- EPS past 3/5Y- 10.20% ROIC-18.90% 52W Low0.86 39.53% Perf 3Y-52.19%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin0.67% Volatility6.30% 14.79% Perf 5Y-14.89%
Dividend TTM- EV/Sales21.27 EPS Y/Y TTM65.44% Oper. Margin-481.60% ATR (14)0.16 Perf 10Y-94.53%
Dividend Ex-Date- Quick Ratio0.61 Sales Y/Y TTM- Profit Margin-227.72% RSI (14)51.39 Recom1.00
Dividend Gr. 3/5Y- - Current Ratio0.61 EPS Q/Q44.23% SMA202.66% Beta1.07 Target Price6.00
Payout- Debt/Eq0.03 Sales Q/Q- SMA50-1.58% Rel Volume1.03 Prev Close1.17
Employees11 LT Debt/Eq0.00 Earnings- SMA200-27.12% Avg Volume32.74K Price1.20
IPOSep 01, 2005 Option/ShortNo / Yes EPS/Sales Surpr.- - Trades Volume33,148 Change2.13%
Date Action Analyst Rating Change Price Target Change
May-08-15Initiated H.C. Wainwright Buy $6
Apr-07-25 09:15AM
Aug-14-24 09:15AM
Jun-17-24 07:40AM
Jun-05-24 09:15AM
May-13-24 07:23AM
07:33AM Loading…
Apr-29-24 07:33AM
Mar-20-24 10:15AM
Oct-20-23 04:00PM
04:00PM
Nov-21-18 08:00AM
Nov-01-18 10:09AM
Jul-24-18 09:09AM
May-29-18 05:37PM
Dec-13-17 07:30AM
Dec-06-17 12:08PM
10:30AM Loading…
Nov-27-17 10:30AM
Oct-23-17 11:23AM
Oct-06-17 07:30AM
Oct-05-17 07:50AM
Sep-26-17 09:23AM
Sep-12-17 09:00AM
Jul-11-17 07:00AM
Jun-15-17 09:00AM
Apr-27-17 09:50AM
Apr-05-17 09:10AM
Mar-30-17 08:55AM
Mar-22-17 09:22AM
Mar-07-17 12:40PM
Mar-01-17 08:30AM
Feb-17-17 08:00AM
09:08AM Loading…
Feb-13-17 09:08AM
Jan-25-17 08:30AM
Jan-05-17 08:30AM
Dec-19-16 08:00AM
Dec-06-16 08:30AM
Nov-09-16 01:25PM
Sep-27-16 08:30AM
Sep-07-16 08:32AM
Sep-06-16 08:00AM
Aug-11-16 09:00AM
Jun-02-16 09:11AM
Jun-01-16 08:30AM
May-16-16 11:45AM
Apr-07-16 01:04PM
Mar-31-16 09:45AM
Mar-21-16 08:30AM
Mar-09-16 08:29AM
Mar-02-16 09:00AM
Feb-22-16 09:02AM
Feb-10-16 08:30AM
Jan-27-16 08:30AM
Jan-25-16 08:30AM
Jan-13-16 08:30AM
Jan-11-16 08:30AM
Dec-01-15 08:30AM
Nov-09-15 08:30AM
Oct-28-15 09:00AM
Oct-26-15 09:15AM
Oct-13-15 08:45AM
Sep-17-15 11:40AM
Sep-03-15 09:00AM
Sep-01-15 09:00AM
Aug-26-15 09:00AM
Jun-01-15 08:00AM
May-11-15 10:50AM
May-09-15 09:45AM
May-08-15 09:35AM
07:43AM
Apr-28-15 07:45AM
Mar-31-15 09:30AM
Feb-17-15 08:30AM
Dec-30-14 12:23PM
Dec-08-14 08:30AM
Dec-01-14 08:00AM
Sep-02-14 12:09PM
Jul-22-14 02:54PM
Jul-16-14 09:18AM
Jun-12-14 08:00AM
Jun-02-14 09:00AM
May-19-14 08:00AM
Apr-02-14 04:41PM
Mar-25-14 08:00AM
Jan-08-14 08:00AM
XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its product pipeline includes hCDR1 and rHuEPO. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.